iSpecimen Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 40 rows, 40 shown. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2024-09-25: Reporting owner Dhaliwal Avtar; Form 4; Security Option; Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2024-09-25: Reporting owner Paolone Richard; Form 4; Security Option; Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2024-09-25: Reporting owner Field Katharyn; Form 4; Security Option; Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2024-03-21: Reporting owner Graham Elizabeth Ames; Form 4; Security Option; Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
ISPC insiders transactions against the stock price
Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
Markers: each transaction type positioned at that session's split-adjusted close. Tooltips retain the reported transaction price when available.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2024-09-25 | Dhaliwal Avtar Director | 4 | Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +168 168 owned after | $5.12 | $206.80 | 2024-09-30 |
| 2024-09-25 | Paolone Richard Director | 4 | Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +168 168 owned after | $5.12 | $206.80 | 2024-09-27 |
| 2024-09-25 | Field Katharyn Director | 4 | Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +168 168 owned after | $5.12 | $206.80 | 2024-09-27 |
| 2024-03-21 | Graham Elizabeth Ames Director | 4 | Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,340 8,340 owned after | $0.28 | $220.00 | 2024-05-20 |
| 2024-02-08 holding as of filing | Mock Theresa L Director | 5 | Non-Qualified Stock Options Derivative · Direct | Holding | 6,672 owned after | $1.37 exercise price | 2024-02-08 | |
| 2024-01-02 | Ross Andrew L. Director | 4 | Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 33,525 owned after | $0.53 | $420.00 | 2024-05-20 |
| 2024-01-02 | Mock Theresa L Director | 4 | Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 16,672 owned after | $0.53 | $420.00 | 2024-05-20 |
| 2024-01-02 | Gullans Steven R. Ph.D. Director | 4 | Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 33,525 owned after | $0.53 | $420.00 | 2024-05-20 |
| 2024-01-02 | Brooks John L. III Director | 4 | Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 33,525 owned after | $0.53 | $420.00 | 2024-05-20 |
| 2023-01-17 | Mullan Jill Director | 4 | Option Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −66,637 10,000 owned after | $1.00 exercise price | $1,296.00 | 2023-01-19 |
| 2023-01-06 | Ianelli Christopher Director | 4 | Option Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −845 10,000 owned after | $1.00 exercise price | $1,136.00 | 2023-01-19 |
| 2023-01-03 | Ianelli Christopher Director | 4 | Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,845 owned after | $1.41 | $1,128.00 | 2023-01-19 |
| 2023-01-03 | Mullan Jill Director | 4 | Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 76,637 owned after | $1.41 | $1,128.00 | 2023-01-19 |
| 2023-01-03 | Gullans Steven R. Ph.D. Director | 4 | Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 23,525 owned after | $1.41 | $1,128.00 | 2023-01-13 |
| 2023-01-03 | Basile Joseph J. Director | 4 | Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 11,668 owned after | $1.41 | $1,128.00 | 2023-01-13 |
| 2023-01-03 | Brooks John L Director | 4 | Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 23,525 owned after | $1.41 | $1,128.00 | 2023-01-13 |
| 2023-01-03 | Scholl George H. Director | 4 | Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 23,525 owned after | $1.41 | $1,128.00 | 2023-01-13 |
| 2023-01-03 | Ross Andrew L. Director | 4 | Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 23,525 owned after | $1.41 | $1,128.00 | 2023-01-13 |
| 2022-12-01 holding as of filing | Basile Joseph J. Director | 3 | Option Derivative · Direct | Holding | $1.50 exercise price | 2022-12-01 | ||
| 2022-11-01 | Curley Tracy Officer (Interim CEO, CFO and Treasurer) | 4 | Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +100,000 100,000 owned after | $1.61 | $1,288.00 | 2022-11-04 |
| 2022-11-01 | Bielak Benjamin Officer (Chief Information Officer) | 4 | Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 57,952 owned after | $1.61 | $1,288.00 | 2022-11-04 |
| 2022-10-24 | Ianelli Christopher Director | 4 | Option Derivative · Direct | J Other acquisition or disposition (describe transaction) | −564 845 owned after | no price filed | $1,224.00 | 2022-11-14 |
| 2022-10-24 | Mullan Jill Director | 4 | Option Derivative · Direct | J Other acquisition or disposition (describe transaction) | −564 66,637 owned after | no price filed | $1,224.00 | 2022-11-10 |
| 2022-02-23 | Ianelli Christopher Director, Officer (President & CEO) | 4 | Option Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −48,106 1,409 owned after | $1.00 exercise price | $3,272.00 | 2022-02-24 |
| 2022-02-22 | Ianelli Christopher Director, Officer (President & CEO) | 4 | Option Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,099 49,515 owned after | $1.00 exercise price | $2,920.00 | 2022-02-24 |
| 2022-02-22 | Mullan Jill Director, Officer (COO & Secretary) | 4 | Option Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −19,296 70,300 owned after | $1.00 exercise price | $2,920.00 | 2022-02-23 |
| 2022-02-22 | Mullan Jill Director, Officer (COO & Secretary) | 4 | Option Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,099 67,201 owned after | $1.00 exercise price | $2,920.00 | 2022-02-23 |
| 2021-07-30 | Scholl George H. Director | 5 | Non-Qualified Stock Options Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +13,525 13,525 owned after | $8.00 exercise price | $5,024.00 | 2022-02-14 |
| 2021-07-30 | Lawrence Margaret H. Director | 5 | Non-Qualified Stock Options Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +13,525 13,525 owned after | $8.00 exercise price | $5,024.00 | 2022-02-14 |
| 2021-07-30 | Gullans Steven R. Ph.D. Director | 5 | Non-Qualified Stock Options Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +13,525 13,525 owned after | $8.00 exercise price | $5,024.00 | 2022-02-14 |
| 2021-07-30 | Brooks John L Director | 5 | Non-Qualified Stock Options Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +13,525 13,525 owned after | $8.00 exercise price | $5,024.00 | 2022-02-14 |
| 2021-07-30 | Director, 10% Owner | 4 | Non-Qualified Stock Options Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +13,525 13,525 owned after | no price filed | $5,024.00 | 2021-11-29 |
| 2021-06-17 holding as of filing | Mullan Jill Director, Officer (COO, Secretary, Treasurer) | 3 | Option Derivative · Direct | Holding | $1.00 exercise price | 2021-06-17 | ||
| 2021-06-17 holding as of filing | Mullan Jill Director, Officer (COO, Secretary, Treasurer) | 3 | Option Derivative · Direct | Holding | $1.00 exercise price | 2021-06-17 | ||
| 2021-06-17 holding as of filing | Mullan Jill Director, Officer (COO, Secretary, Treasurer) | 3 | Option Derivative · Direct | Holding | $1.00 exercise price | 2021-06-17 | ||
| 2021-06-17 holding as of filing | Gullans Steven R. Ph.D. Director | 3 | Option Derivative · Direct | Holding | $3.83 exercise price | 2021-06-17 | ||
| 2021-06-17 holding as of filing | Ianelli Christopher Director, Officer (CEO, President) | 3 | Option Derivative · Direct | Holding | $1.00 exercise price | 2021-06-17 | ||
| 2021-06-17 holding as of filing | Ianelli Christopher Director, Officer (CEO, President) | 3 | Option Derivative · Direct | Holding | $1.00 exercise price | 2021-06-17 | ||
| 2021-06-16 holding as of filing | Bielak Benjamin Officer (Chief Information Officer) | 3 | Option Derivative · Direct | Holding | $1.00 exercise price | 2021-06-16 | ||
| 2021-06-16 holding as of filing | Bielak Benjamin Officer (Chief Information Officer) | 3 | Option Derivative · Direct | Holding | $1.00 exercise price | 2021-06-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |